Cantor Fitzgerald Reiterates a 'Buy' on Sunesis Pharmaceuticals (SNSS); Market Potential for Vosaroxin

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/15/2026

1. AMAT
2. SPY
3. GLOB
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. ADYYF
10. MU

Go back to Cantor Fitzgerald Reiterates a 'Buy' on Sunesis Pharmaceuticals (SNSS); Market Potential for Vosaroxin

Sunesis Pharma (SNSS) to Boost Sample Size in Phase 3 VALOR of Vosaroxin in AML

September 11, 2012 7:07 AM EDT

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) will implement a one-time, 225-patient sample size increase to its Phase 3 VALOR trial of vosaroxin in acute myeloid leukemia (AML), bringing target enrollment to 675 patients. This is in response to the recommendation of the trial's independent Data and Safety Monitoring... More